By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MorphoSys AG 

Lena-Christ-Strasse 48

Martinsried  Munich  82152  Germany
Phone: 49-0-89-899-27-0 Fax: 49-0-89-899-27-222



Company News
MorphoSys AG Appoints Four R&D Experts To Its Newly Formed Scientific Advisory Board 9/12/2016 6:42:59 AM
MorphoSys AG Initiates Phase 2/3 Trial Of CD19 Antibody MOR208 Plus Bendamustine In Patients With Relapsed Or Refractory DLBCL 9/6/2016 2:28:12 PM
MorphoSys AG Successfully Completes Safety Run-in Of MOR208 In L-MIND Combination Study In Patients With DLBCL 8/3/2016 9:12:12 AM
MorphoSys AG Reports Results For The First Six Months Of 2016 8/1/2016 9:37:31 AM
MorphoSys AG To Host Q2 2016 Conference Call On August 1, 2016 7/25/2016 9:41:24 AM
MorphoSys AG Receives Clinical Milestone For Start Of Phase 1 Trial In Prevention Of Thrombosis With Novel Antibody 7/5/2016 9:15:24 AM
MorphoSys AG Reports Publication Of Clinical Case Report Of A Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission Of Currently 26 Months Under MOR208 Treatment 6/17/2016 9:27:24 AM
ASCO2016: MorphoSys AG Presents Updated Clinical Data For MOR202 In Multiple Myeloma And For MOR208 In Non-Hodgkin's Lymphoma At ASCO 2016 6/6/2016 3:18:48 PM
MorphoSys AG Reports Outcome Of Annual General Meeting 2016 6/2/2016 9:53:26 AM
MorphoSys AG To Present Clinical Trial Data On Proprietary Programs At Upcoming ASCO Annual Meeting 2016 5/19/2016 9:59:12 AM